Abstract: The invention concerns a compound of formula (I) R1=H or acyl group, preferably R1=H; R2=halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2=Cl or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating circadian rhythm sleep disorders and/or circadian rhythm sleep neurological diseases and/or any medical condition associated due to sleep deprivation.

Abstract: The invention concerns a compound of formula (I), wherein R1=halogen atom selected in the group consisting of: F, Cl, Br, I, and R2=H or OH, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating chronic fatigue syndrome.

Abstract: The invention concerns a compound of formula (I) R1=H or halogen atom selected in the group consisting of: F, Cl, Br, I, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating Kleine-Levin syndrome.

Abstract: The present invention relates to mazindol for use in the treatment of dependence and substance use disorder, wherein the substance is an opioid, a composition comprising mazindol and optionally a pharmaceutically acceptable carrier or excipient and/or a diluent, for use in the treatment of substance abuse disorder, wherein the substance is an opioid, and a method of treatment of substance abuse disorder comprising administering mazindol or composition comprising mazindol to a subject, wherein the substance is an opioid. The opioid is preferably heroin.

Abstract: The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.

Abstract: The present invention relates to mazindol for use in the treatment of dependence and substance use disorder, wherein the substance is an opioid, a composition comprising mazindol and optionally a pharmaceutically acceptable carrier or excipient and/or a diluent, for use in the treatment of substance abuse disorder, wherein the substance is an opioid, and a method of treatment of substance abuse disorder comprising administering mazindol or composition comprising mazindol to a subject, wherein the substance is an opioid. The opioid is preferably heroin.

Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.